Related Experiment Video
Updated: May 27, 2025
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Amivantamab plus lazertinib vs. osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer
Nazmul Hasan1, Misako Nagasaka1
1University of California Irvine School of Medicine, Orange, CA, USA.
Introduction:
The first-line treatment landscape for patients with NSCLC harboring sensitizing EGFR mutations is rapidly evolving. Initially, osimertinib was the one and only option over earlier generation EGFR inhibitors based on the positive PFS and OS results from the FLAURA study.
Areas Covered:
This paper reviews and compares the pivotal studies that led to the approval of combination treatment with a focus on the efficacy and safety of amivantamab plus lazertinib in the front-line setting. The literature reviewed in this paper primarily includes key studies published in well-established journals and oncological conferences, such as ASCO, ESMO, and NEJM, between 2018 and 2024.
Expert Opinion:
Recent advancements, including the results of FLAURA-2 and MARIPOSA, have introduced combination therapies that demonstrate enhanced efficacy.
Insights
New combination therapies are improving first-line treatment for non-small cell lung cancer (NSCLC) with EGFR mutations, offering enhanced efficacy over previous single-agent options.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- The treatment of non-small cell lung cancer (NSCLC) with sensitizing epidermal growth factor receptor (EGFR) mutations has evolved.
- Osimertinib was initially the sole first-line treatment option, supported by FLAURA study findings.
Purpose of the Study:
- To review and compare pivotal studies on first-line combination therapies for EGFR-mutated NSCLC.
- To focus on the efficacy and safety of amivantamab plus lazertinib.
Main Methods:
- Literature review of key studies published between 2018-2024.
- Inclusion of studies from major oncological conferences and journals (ASCO, ESMO, NEJM).
Main Results:
- Recent studies like FLAURA-2 and MARIPOSA demonstrate enhanced efficacy with combination therapies.
- Amivantamab plus lazertinib shows promising results in the front-line setting.
Conclusions:
- Combination therapies represent a significant advancement in first-line treatment for EGFR-mutated NSCLC.
- Amivantamab plus lazertinib is a key option in this evolving landscape.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
